Clarke SJ - Search Results

1

Cancer-related inflammation and treatment effectiveness.

Diakos CI, Charles KA, McMillan DC, Clarke SJ. Diakos CI, et al. Among authors: clarke sj. Lancet Oncol. 2014 Oct;15(11):e493-503. doi: 10.1016/S1470-2045(14)70263-3. Lancet Oncol. 2014. PMID: 25281468 Review.

2

Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy.

Slaviero KA, Clarke SJ, Rivory LP. Slaviero KA, et al. Among authors: clarke sj. Lancet Oncol. 2003 Apr;4(4):224-32. doi: 10.1016/s1470-2045(03)01034-9. Lancet Oncol. 2003. PMID: 12681266 Review.

3

Factors affecting cytochrome P-450 3A activity in cancer patients.

Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A. Baker SD, et al. Among authors: clarke sj. Clin Cancer Res. 2004 Dec 15;10(24):8341-50. doi: 10.1158/1078-0432.CCR-04-1371. Clin Cancer Res. 2004. PMID: 15623611

4

Predicting the toxicity of weekly docetaxel in advanced cancer.

Charles KA, Rivory LP, Stockler MR, Beale P, Beith J, Boyer M, Clarke SJ. Charles KA, et al. Among authors: clarke sj. Clin Pharmacokinet. 2006;45(6):611-22. doi: 10.2165/00003088-200645060-00004. Clin Pharmacokinet. 2006. PMID: 16719542 Clinical Trial.

5

Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.

Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Charles KA, et al. Among authors: clarke sj. Clin Cancer Res. 2006 Dec 15;12(24):7492-7. doi: 10.1158/1078-0432.CCR-06-0023. Clin Cancer Res. 2006. PMID: 17189422

6

Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer.

Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ. Morgan ET, et al. Among authors: clarke sj. Drug Metab Dispos. 2008 Feb;36(2):205-16. doi: 10.1124/dmd.107.018747. Drug Metab Dispos. 2008. PMID: 18218849

7

Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing.

Kacevska M, Robertson GR, Clarke SJ, Liddle C. Kacevska M, et al. Among authors: clarke sj. Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):137-49. doi: 10.1517/17425255.4.2.137. Expert Opin Drug Metab Toxicol. 2008. PMID: 18248309 Review.

8

Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.

Chua W, Moore MM, Charles KA, Clarke SJ. Chua W, et al. Among authors: clarke sj. Curr Opin Mol Ther. 2009 Dec;11(6):611-22. Curr Opin Mol Ther. 2009. PMID: 20072938 Review.

9

Inflammation and cancer: causes and consequences.

Moore MM, Chua W, Charles KA, Clarke SJ. Moore MM, et al. Among authors: clarke sj. Clin Pharmacol Ther. 2010 Apr;87(4):504-8. doi: 10.1038/clpt.2009.254. Epub 2010 Feb 10. Clin Pharmacol Ther. 2010. PMID: 20147899 Review.

10

Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.

Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ. Chua W, et al. Among authors: clarke sj. Crit Rev Oncol Hematol. 2011 Sep;79(3):224-50. doi: 10.1016/j.critrevonc.2010.07.012. Epub 2010 Aug 16. Crit Rev Oncol Hematol. 2011. PMID: 20719530 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

389 results

Search Page